Delta opioid receptor ligands modulate anxiety-like behaviors in the rat

British Journal of Pharmacology

Volumn 147, Issue 8, 2006, Pages 864-872

  Perrine, Shane A ^a   Hoshaw, Brian A ^b   Unterwald, Ellen M ^a,c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Anxiety; Defensive burying paradigm; Delta opioid receptor; Elevated plus maze; Locomotion; Naltrindole; Rat; SNC80

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; AMPHETAMINE; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DIAZEPAM; NALTRINDOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ANXIETY LIKE BEHAVIOR; ARTICLE; CONTROLLED STUDY; DEFENSIVE BURYING PARADIGM; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL TEST; HYPERACTIVITY; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NALTREXONE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA;

EID: 33646560615     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706686     Document Type: Article

References (39)

1. BERRENDERO, F. & MALDONADO, R. (2002). Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berlin), 163, 111-117.
2. BILSKY, E.J., CALDERON, S.N., WANG, T., BERNSTEIN, R.N., DAVIS, P., HRUBY, V.J., MCNUTT, R.W., ROTHMAN, R.B., RICE, K.C. & PORRECA, F. (1995). SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J. Pharmacol. Exp. Ther., 273, 359-366.
3. BROOM, D.C., JUTKIEWICZ, E.M., FOLK, J.E., TRAYNOR, J.R., RICE, K.C. & WOODS, J.H. (2002a). Convulsant activity of a nonpeptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berlin), 164, 42-48.
4. BROOM, D.C., JUTKIEWICZ, E.M., FOLK, J.E., TRAYNOR, J.R., RICE, K.C. & WOODS, J.H. (2002b). Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology, 26, 744-755.
5. BROOM, D.C., JUTKIEWICZ, E.M., RICE, K.C., TRAYNOR, J.R. & WOODS, J.H. (2002c). Behavioral effects of delta-opioid receptor agonists: potential antidepressants? Jpn. J. Pharmacol., 90, 1-6.
6. CALDERON, S.N. & COOP, A. (2004). SNC 80 and related delta opioid agonists. Curr. Pharm., 10, 733-742.
7. CALDERON, S.N., ROTHMAN, R.B., PORRECA, F., FLIPPEN-ANDERSON, J.L., MCNUTT, R.W., XU, H., SMITH, L.E., BILSKY, E.J., DAVIS, P. & RICE, K.C. (1994). Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist. J. Med. Chem., 37, 2125-2128.
8. DAWSON, G.R. & TRICKLEBANK, M.D. (1995). Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol. Sci., 16, 33-36.
9. DE BOER, S.F. & KOOLHAAS, J.M. (2003). Defensive burying in rodents: ethology, neurobiology and psychopharmacology. Eur. J. Pharmacol., 463, 145-161.
10. FEKETE, M.I., HORVATH, K., KEDVES, R., MATE, I., SZEKELY, J.I. & SZENTKUTI, E. (1997). Selective interaction of homophtalazine derivatives with morphine. Eur. J. Pharmacol., 331, 175-183.
11. FERNANDES, C. & FILE, S.E. (1996). The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol. Biochem. Behav., 54, 31-40.
12. FILLIOL, D., GHOZLAND, S., CHLUBA, J., MARTIN, M., MATTHES, H.W., SIMONIN, F., BEFORT, K., GAVERIAUX-RUFF, C., DIERICH, A., LEMEUR, M., VALVERDE, O., MALDONADO, R. & KIEFFER, B.L. (2000). Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet., 25, 195-200.
13. GAWIN, F.H. (1991). Cocaine addiction: psychology and neurophysiology. Science, 251, 1580-1586.
14. HANDLEY, S.L. & MCBLANE, J.W. (1993). An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J. Pharmacol. Toxicol. Methods, 29, 129-138.
15. JUTKIEWICZ, E.M., ELLER, E.B., FOLK, J.E., RICE, K.C., TRAYNOR, J.R. & WOODS, J.H. (2004). Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J. Pharmacol. Exp. Ther., 309, 173-181.
16. JUTKIEWICZ, E.M., RICE, K.C., WOODS, J.H. & WINSAUER, P.J. (2003). Effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats. Behav. Pharmacol., 14, 509-516.
17. KNAPP, R.J., SANTORO, G., DE LEON, I.A., LEE, K.B., EDSALL, S.A., WAITE, S., MALATYNSKA, E., VARGA, E., CALDERON, S.N., RICE, K.C., ROTHMAN, R.B., PORRECA, F., ROESKE, W.R. & YAMAMURA, H.I. (1996). Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. J. Pharmacol. Exp. Ther., 277, 1284-1291.
18. KOSTEN, T.R., GAWIN, F.H., ROUNSAVILLE, B.J. & KLEBER, H.D. (1986). Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment. Am. J. Drug Alcohol Abuse, 12, 1-16.
19. KREEK, M.J., BOR, G.L., ZHOU, Y. & SCHLUGER, J. (2002). Relationship between endocrine functions and substance abuse syndromes: Heroin and related short-acting opiates in addiction contrasted with methadone and other long-acting opioid agonists used in pharmacotherapy of addiction. In: Hormones, Brain and Behavior. Academic Press, San Diego. ed. Pfaff, D., pp. 781-830.
20. MARIN, S., MARCO, E., BISCAIA, M., FERNANDEZ, B., RUBIO, M., GAUZA, C., SCHMIDHAMMER, H. & VIVEROS, M.P. (2003). Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol. Biochem. Behav., 74, 649-656.
21. NEILAN, C.L., AKIL, H., WOODS, J.H. & TRAYNOR, J.R. (1999). Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists. Br. J. Pharmacol., 128, 556-562.
22. NIETO, M.M., GUEN, S.L.E., KIEFFER, B.L., ROQUES, B.P. & NOBLE, F. (2005). Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors. Neuroscience, 135, 305-313.
23. O'BRIEN, C.P. (2001). Drug Addiction and Drug Abuse. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th edition.. McGraw-Hill, New York. eds. HARDMAN, J.G., LIMBIRD, L.E., GILMAN, A.G., pp. 633-636.
24. PACHECO, D.F., REIS, G.M., FRANCISCHI, J.N., CASTRO, M.S., PEREZ, A.C. & DUARTE, I.D. (2005). delta-Opioid receptor agonist SNC80 elicits peripheral antinociception via delta(1) and delta(2) receptors and activation of the 1-arginine/nitric oxide/cyclic GMP pathway. Life Sci., 78, 54-60.
25. PATTERSON, J.P., MARKGRAF, C.G., CIRINO, M. & BASS, A.S. (2005). Validation of a motor activity system by a robotically controlled vehicle and using standard reference compounds. J. Pharmacol. Toxicol. Methods, 52, 159-167.
26. PELLOW, S., CHOPIN, P., FILE, S.E. & BRILEY, M. (1985). Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods, 14, 149-167.
27. PLOBECK, N., DELORME, D., WEI, Z.Y., YANG, H., ZHOU, F., SCHWARZ, P., GAWELL, L., GAGNON, H., PELCMAN, B., SCHMIDT, R., YUE, S.Y., WALPOLE, C., BROWN, W., ZHOU, E., LABARRE, M., PAYZA, K., ST-ONGE, S., KAMASSAH, A., MORIN, P.E., PROJEAN, D., DUCHARME, J. & ROBERTS, E. (2000). New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased in vitro metabolic stability. J. Med. Chem., 43, 3878-3894.
28. PORTOGHESE, P.S., SULTANA, M. & TAKEMORI, A.E. (1988). Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur. J. Pharmacol., 146, 185-186.
29. PRESOLD, C. & TREIT, D. (1992). Excitotoxic lesions of the septum produce anxiolytic effects in the elevated plus-maze and the shock-probe burying tests. Physiol. Behav., 52, 37-47.
30. SAITOH, A., KIMURA, Y., SUZUKI, T., KAWAI, K., NAGASE, H. & KAMEI, J. (2004). Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J. Pharmacol. Sci., 95, 374-380.
31. SAITOH, A., YOSHIKAWA, Y., ONODERA, K. & KAMEI, J. (2005). Role of δ-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats. Psychopharmacology, 182, 327-334.
32. SIBILLE, E. & HEN, R. (2001). Combining genetic and genomic approaches to study mood disorders. Eur. Neuropsychopharmacol., 11, 413-421.
33. SIPOS, M.L., BURCHNELL, V. & GALBICKA, G. (1999). Dose-response curves and time-course effects of select5ed anticholinergics on locomotor activity in rats. Psychopharmacology, 147, 250-256.
34. STARK, K.L. & HEN, R. (1999). Knockout Corner. Int. J. Neuropsychopharmacol., 2, 145-150.
35. TREIT, D., PINEL, J.P. & FIBIGER, H.C. (1981). Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol. Biochem. Behav., 15, 619-626.
36. TRYOEN-TOTH, P., DECAILLOT, P.M., FILLIOL, D., BEFORT, K., LAZARUS, L.H., SCHILLER, P.W., SCHMIDHAMMER, H. & KIEFFER, B.L. (2005). Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid receptors. J. Pharmacol. Exp. Ther., 313, 410-421.
37. VARONA, A., GIL, J., SARACIBAR, G., MAZA, J.L., ECHEVARRIA, E. & IRAZUSTA, J. (2003). Effects of imipramine treatment on delta-opioid receptors of the rat brain cortex and striatum. Arzneimittelforschung, 53, 21-25.
38. ZAKI, P.A., KEITH JR, D.E., THOMAS, J.B., CARROLL, F.I. & EVANS, C.J. (2001). Agonist-, antagonist-, and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation. J. Pharmacol. Exp. Ther., 298, 1015-1020.
39. ZHUANG, X., GROSS, C., SANTARELLI, L., COMPAN, V., TRILLAT, A.C. & HEN, R. (1999). Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharm., 21 (2 Suppl), 52S-60S.